Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Otsuka, Bristol-Myers Squibb Withdraw Abilify Extension Application In Europe

This article was originally published in PharmAsia News

Executive Summary

Japan's fifth-largest drug maker Otsuka Pharmaceutical withdrew its application in Europe for the additional indication of major depressive episodes for its best-selling atypical antipsychotic Abilify (aripiprazole), the European Medicines Agency announced Nov. 19

You may also be interested in...

BMS' Abilify Gains Third Pediatric Indication: Autism-Related Irritability

New claim puts the atypical antipsychotic on par with J&J's Risperdal.

BMS & Otsuka Expand Their Abilify Deal, Enter into New Oncology Co-Promotion

Bristol-Myers Squibb and Japanese partner Otsuka Pharmaceuticals have entered into a two-part deal that extends their 10-year-old collaboration to sell the blockbuster psychiatric drug Abilify (aripiprazole) in the U.S. and also gives Otsuka a presence in oncology in the U.S., Europe and Japan

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts